Skip to main content

Table 5 Association of efficacy with treatment strategies in RET fusion positive NSCLC

From: Therapeutic strategies in RET gene rearranged non-small cell lung cancer

Agent

ORR (%)

mPFS (mo)

mOS (mo)

Common Gr 3 or 4 AEs

Refs

Selpercatinib (first line)

85

NR

 

Hypertension, elevated AST, ALT,

[27]

Pralsetinib (first line)

73

NR

 

Anemia, hypertension, Neutropenia,

[32]

Vandetanib

18

4.5

11.6

Hypertension, diarrhea, rash, dry skin, QT prolongation

[41]

Cabozantinib

28

5.5

9.9

Elevated lipase, ALT, AST, thrombocytopenia, hypophosphatemia

[42]

CPI (Nivolumab or Pembrolizumab)

12.7

3.4 (95% CI 1.7–6.2)

18.4 (95% CI 7.0–NR)

NA

[8]

Platinum-Pemetrexed (first line)

50

9.2

26.4

NA

[37]

  1. CPI, Checkpoint inhibitor; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; NA, Not available (these were retrospective studies focused on efficacy)